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Abstract
Purpose—Dry eye disease (DED) is an ocular disease that affects 5% to 17% of the US
population. Because of the negative effects of DED on patients’ quality of life (QOL), disease-
specific questionnaires that assess QOL in patients with dry eyes are essential in the monitoring
and management of this chronic ocular condition. This review provides clinicians and researchers
with a summary of the current questionnaires available for assessing QOL in patients with dry
eyes.
Methods—A systematic review of the literature was performed in March 2013.
Results—There are only 2 validated, reliable dry eye questionnaires with QOL measures
currently available for clinic use: the Ocular Surface Disease Index (OSDI) and the Impact of Dry
Eye on Everyday Life questionnaire (IDEEL). Multiple other dry eye questionnaires assess some
degree of QOL, but they have either not been tested for validity and reliability or are limited in
QOL measures they assess.
Conclusions—The OSDI and IDEEL are validated, reliable disease-specific questionnaires that
assess QOL measures in patients with DED. Because of its extensive development process and
multiple QOL measures, the IDEEL offers a more thorough assessment of the effect of DED on
QOL for clinical trials, whereas the OSDI may be the more convenient option for clinical use as a
result of its shorter completion time. Other questionnaires used to assess QOL in DED (eg, 25-
item National Eye Institute Visual Function Questionnaire and Texas Eye Research and
Technology Center DEQ) are fairly limited in this assessment. Finally, because of the negative
effects of DED on QOL, this review emphasizes the importance of including QOL measures in
future questionnaires for the monitoring and management of DED.
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Dry eye disease (DED) is a common ocular disease characterized by eye pain, burning,
foreign body sensation, and ocular surface irritation.1,2 This disease affects 5% to 17% of
the US population, and the evidence that DED can greatly diminish quality of life (QOL) in
the affected population is steadily increasing.2–6 Recent QOL studies of DED show that
moderate-to-severe dry eye can cause a decrease in the QOL comparable with that in
dialysis, severe angina, and disabling hip fractures.6,7
Several clinical dry eye tests are readily available to help monitor the severity of DED,
including fluorescein staining, tear break-up time, lissamine green staining, Schirmer test
type 1, Schirmer test type 2, and many other clinical measures.2,8,9 Unfortunately, these tests
correlate poorly with patient symptoms and QOL measures in patients with dry eyes.2
Nevertheless, these objective tests, including a novel test for measuring tear film osmolarity,
are vitally important in the screening and diagnosis of DED because multiple studies have
shown that many patients with DED are largely asymptomatic and would not be diagnosed
by a symptom-based screening method alone.10,11 At the same time, the limited correlation
between signs and symptoms makes assessing QOL of DED patients through patient-
reported questionnaires an important component of DED monitoring and management
because many patients are more symptomatic and have a worse QOL than their clinical
signs alone may suggest.1,12 In addition, the Federal Food and Drug Administration (FDA)
has increased their emphasis on properly developing and using patient-reported outcomes
(PROs), such as QOL measures, in clinical drug trials to determine treatment efficacy.13 As
a result of this increased emphasis on proper PRO development and the weak correlation of
clinical tests to patient-reported symptoms in DED, it is essential that ophthalmologists be
aware of PRO questionnaires currently available for assessing QOL in patients with dry
eyes.
The International Dry Eye Workshop highlighted several of these questionnaires in its 2007
epidemiology report on DED; however, it only provided brief descriptions of the
questionnaires available for assessing QOL in patients with dry eyes.8 Subsequently, in
2010, Alcon, inc. (Ft. Worth, TX) funded and coordinated a systematic review of PRO
instruments available for use in clinical trials involving DED. The authors based their
review on the 2007 Dry Eye Workshop report and their own 2010 literature search. This
2010 review highlights several dry eye questionnaires that assess QOL and provide detailed
descriptions of and recommendations for these PRO instruments.12 Yet, no other systematic
reviews have been performed since that time to confirm the results of this study even though
more work on dry eye questionnaires has been published since their literature review.4,14,15
Therefore, the current review article seeks to provide clinicians and researchers with an
update on the dry eye questionnaires currently available to assess QOL in patients with
DED.
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A systematic review of the literature was performed at the University of North Carolina in
March 2013, to determine the validated, reliable dry eye questionnaires with QOL measures
that are currently available for clinicians and researchers to use. Because of the FDA’s
recent emphasis on proper PRO development, a “validated, reliable dry eye questionnaire
with QOL measures” was defined as a questionnaire that is disease specific, has undergone
validity and reliability testing (including test–retest reliability) in a DED population,
includes QOL measures, and has been developed and tested in the English language. This
review was not externally funded.
RESULTS
Two validated, reliable dry eye questionnaires that include QOL measures are currently
available for clinic use: the Ocular Surface Disease Index (OSDI) and the Impact of Dry Eye
on Everyday Life questionnaire (IDEEL).2,9,14,16 These 2 questionnaires are summarized in
detail below. This systematic review also uncovered 7 other questionnaires used in DED
populations that assess some degree of QOL, but these questionnaires do not meet the
aforementioned criteria for being a validated, reliable dry eye questionnaire with QOL
measures. Because these questionnaires may still prove useful as a supplement to the OSDI
and IDEEL, however, a brief overview of these questionnaires has been provided as well.
The OSDI
Description—The OSDI is a 12-item questionnaire that assesses both dry eye symptoms
and their effects on vision-related functioning over the past week. It contains 3 subsections
including vision-related function, ocular symptoms, and environmental triggers.1,9,12
Patients are asked about the frequency of occurrence of various symptoms and difficulty
encountered with vision-related activities and for their response on a 0 to 4 scale that ranges
from “none of the time” to “all of the time.” The final score is calculated by multiplying the
sum of all the scores by 25 and then dividing the total by the number of questions
answered.9 Scores range from 0 to 100 with 0 to 12 representing normal, 13 to 22 mild
DED, 23 to 32 moderate DED, and • 33 severe DED.9,17
Validity and Reliability Testing—The OSDI has undergone substantial validity and
reliability testing since its initial development.9,12 The OSDI as a whole and its 3 subscales
individually are all internally consistent and display good-to-excellent test–retest
reliability.2,9 Although the questionnaire is only weakly correlated with clinical dry eye
tests, it is strongly correlated with several other dry eye questionnaires and has moderate
correlations with artificial tear usage.9 The scale is capable of accurately discriminating
between normal, mild-to-moderate, and severe DED.12 In addition, a minimal clinically
important difference has been determined for mild-to-moderate disease (4.5–7.3) and severe
disease (7.3–13.4).2,12,17
QOL Measures—The main QOL measures in the OSDI are in its vision-related function
subscale. This subscale consists of 6 questions that assess the frequency of problems with
vision and vision-related activities such as reading, watching television, driving, and using a
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computer or an automated teller machine.8,16 These 6 questions are included in the overall
OSDI score and can be computed into their own vision-related function subscale score as
well.9
Limitations—One limitation of the OSDI is that it only includes some dry eye symptoms
such as grittiness, sensitivity to light, and pain but does not include other symptoms such as
foreign body sensation and tearing.14,16 It also only discusses some of the effects of DED on
vision-related functioning; therefore, it may not capture the entire effect of DED on a
patient’s daily living.14 In addition, OSDI responses are limited to measures of frequency
(rather than to frequency and severity).18 A second limitation of the OSDI is the effort
required to complete and score the scale, which may consume valuable clinic time in a
practice.19
Overall Utility—Overall, the OSDI is a valid, reliable dry eye questionnaire that at least
partially captures the effects of DED on QOL. Even with its limitations, the OSDI has
proven to be a valuable PRO measure in clinical trials and in ophthalmology clinics.1,9,12
The IDEEL
Description—The IDEEL is a 3-module questionnaire with 57 questions, and it assesses
dry eye symptoms, the effect of DED on QOL, and treatment satisfaction over the past 2
weeks.8,14,15 The 3 modules consist of 6 scales that are outlined below:
• Dry eye impact on daily life: activity limitations, work limitations, and emotional
impact.
• Dry eye treatment satisfaction: satisfaction with treatment and treatment-related
inconvenience.
• Dry eye symptom (-related) bother (which is its own scale).2,14
• Each module is scored from 0 to 100. Higher scores on the impact on daily life
module and treatment satisfaction module indicate a better QOL and higher
treatment satisfaction. Higher scores on the symptom bother module indicate more
bothersome dry eye symptoms.14 For the symptom bother module, 40.0 (6 7.5) is
the average score of patients with mild DED, 50.6 (6 11.0) for patients with
moderate DED, and 64.3 (6 8.0) for patients with severe DED.12
Validity and Reliability—The IDEEL meets the new FDA PRO instrument development
guidelines and has undergone significant validity and reliability testing.14 In addition,
content validity has been confirmed by strong evidence of item saturation (ie, multiple
interviews confirmed that the questionnaire included the relevant questions needed to
achieve its assessment objective).12,14 The questionnaire is internally consistent and has
good test–retest reliability.12 The IDEEL weakly correlates with clinical dry eye tests and
generic QOL questionnaires (Short Form-36 and EuroQoL-5D). In addition, its modules
have mild-to-strong correlations with the dry eye questionnaire.5,14 The Symptom Bother
and Impact on Daily Life modules are able to discriminate among mild, moderate, and
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severe DED.4,12 In addition, a minimal clinically important difference of 12 points has been
determined for the Symptom Bother module.20
QOL Measures—The IDEEL has an entire module dedicated to assessing the effects of
DED on a patient’s QOL. The Impact on Daily Life module consists of 31 questions that
assess the effects of DED on a patient’s emotions (eg, irritability, sadness), activities (eg,
driving, doing close work), and work (eg, difficulty concentrating, feeling distracted).14
These 31 questions ultimately produce a score for the entire Impact of Daily Life module.14
Finally, the IDEEL’s Impact on Daily Life and Symptom Bother modules are better able to
discriminate among mild, moderate, and severe DED than can other QOL questionnaires
such as the Short Form-36 and EuroQoL-5D.5
Limitations—The primary limitation of the IDEEL is that it takes approximately 30
minutes to complete the entire questionnaire.2 This limitation is partially offset by the fact
that individual modules can be used in practice rather than the entire questionnaire.1 One
final limitation of the IDEEL is that it must be purchased for use.1
Overall Utility—The IDEEL is a valid, reliable dry eye questionnaire that does an
excellent job of assessing the effects of DED on QOL. It contains the most QOL measures
of any current dry eye questionnaire. Its overall utility is somewhat uncertain because of its
recent development and thus limited use in recent clinical trials, but it holds promise at
being an important PRO questionnaire for measuring QOL in patients with DED.1,8 In
addition to its cost, the major limitation of this questionnaire’s use in practice may be that it
is time consuming. This limitation, however, may not be as restricting in clinical trials.
Other Questionnaires
Although the OSDI and IDEEL are the only 2 disease-specific, validated, reliable
questionnaires that assess the effect of DED on QOL, other questionnaires have been used to
assess QOL measures in patients with DED. The 25-item National Eye Institute Visual
Function Questionnaire (NEI-VFQ-25) assesses the effect of various eye diseases on
QOL.1,21 It is not disease specific, but it has been tested in patients with dry eyes, and it
displays a modest to strong correlation with the OSDI.1,6,7,12,18 Of particular note, the NEI-
VFQ-25’s ocular pain subscale had the strongest overall correlation with the OSDI leading
some researchers to suggest that patients with low ocular pain scores on the NEI-VFQ-25
should undergo further dry eye testing.18,22 Limitations of the NEI-VFQ-25 for assessing
QOL in patients with dry eyes are that it is not disease specific, needs further validity and
reliability testing in a dry eye population, lacks a specified recall period, and requires 10
minutes to administer the questionnaire.1,12
The original DEQ and the contact lens dry eye questionnaire (includes extra questions for
contact lens wearers) include questions about DED symptoms affecting daily activities, but
overall, both questionnaires (and subsequent variations of these questionnaires) include very
few QOL measures and need reliability testing.12,23,24 The Texas Eye Research and
Technology Center DEQ is a 33-item questionnaire based on the original dry eye
questionnaire that adds several components to the original dry eye questionnaire, including 2
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questions on the disease effect on QOL.12,25 The questionnaire has undergone some validity
testing and can discriminate between normal patients and patients with moderate dry eyes.
Limitations of the questionnaire for measuring QOL in patients with dry eyes include the
need for further test–retest reliability testing. In addition, only a small portion of the
questionnaire is dedicated to QOL measures.25 Thus, these 3 questionnaires are fairly
limited in their ability to assess the effect of DED on QOL.
Several other dry eye questionnaires reported in the literature include QOL measures. First,
an 11-Question Dry Eye Syndrome Questionnaire including DED-specific QOL questions
was used among participants in the Women’s Health Study and Physicians’ Health Study to
determine the effects of dry eye on daily living.3 Second, a Single Item Score dry eye
questionnaire that attempts to quantify dryness-caused discomfort was used in a recent study
to determine whether or not patients with dry eyes were currently symptomatic; this
questionnaire showed strong correlations with the OSDI and some clinical tests.12,26 Both
these questionnaires may assess some QOL measures in patients with dry eyes but are
poorly described in the literature and need to undergo substantially more validity and
reliability testing before being recommended for clinical use.3,12
One final DED questionnaire that measures QOL is the Ocular Surface Disease
questionnaire (OSD).12 This includes 4 modules, one of which is QOL (OSD-QOL). The
OSD-QOL module has been clinically validated and displays a low-to-excellent internal
consistency and test–retest reliability.12 Its main limitations include the need for further
validity and reliability testing of the other modules (medical management/history,
symptoms, and treatment satisfaction), lack of data about testing and use in the English
language, and no recall period provided in the questionnaire.12 Once these limitations are
addressed, the OSD may serve as a valuable tool in the clinic.12
CONCLUSIONS
This review provides a brief analysis of the dry eye questionnaires currently available to
assess the vision-related QOL in patients with DED and should assist clinicians and
researchers alike in determining which questionnaire is the best for their individual situation
such as a clinical practice or a clinical trial. To summarize, there are 2 validated, reliable
disease-specific questionnaires that assess QOL measures in patients with DED: the OSDI
and IDEEL. The IDEEL underwent an extensive development process, contains the most
QOL measures of these 2 questionnaires, and may offer the best assessment of the effect of
DED on QOL for clinical trials. The OSDI, however, can be completed much more quickly
than the IDEEL can, is free for use, and thus may be the more convenient option for use in
the clinic. Other questionnaires (eg, NEI-VFQ-25 and Texas Eye Research and Technology
Center DEQ) can be used to assess QOL in patients with dry eyes but are extremely limited
in this assessment because of a lack of QOL measures or a lack of validity and reliability
testing. This review highlights the need for further testing of these dry eye questionnaires.
Finally, multiple studies continue to show DED’s deleterious effects on patients’ QOL, and
PRO questionnaires remain one of the best ways to measure this disease effect on a patient’s
daily living.12 This review emphasizes the importance of including such QOL measures in
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future PRO questionnaires for DED. An increased emphasis on QOL in dry eye
questionnaires will not only provide valuable outcome data for clinical trials but will also
assist in the clinical treatment and management of DED.
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